Get the Stockscreener App
60.42
1.97%
-1.61
Dianthus Therapeutics Inc stock is traded at $60.42, with a volume of 292.60K.
It is down -1.97% in the last 24 hours and up +30.55% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$62.03
Open:
$60.9
24h Volume:
292.60K
Relative Volume:
0.40
Market Cap:
$2.61B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-18.59
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+14.50%
1M Performance:
+30.55%
6M Performance:
+129.47%
1Y Performance:
+167.18%
1-Day Range:
$60.24
$62.58
1-Week Range:
$52.07
$64.67
52-Week Range:
$13.37
$64.67
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
60.35 | 2.68B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.24 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? - Yahoo Finance
Whats the outlook for Dianthus Therapeutics Incs sectorQuarterly Market Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at 58.45 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighShould You Buy? - MarketBeat
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Guggenheim raises Dianthus Therapeutics stock price target to $200 on autoimmune potential - Investing.com Canada
Dianthus Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
DNTH: Accelerated CIDP and MMN trials target 2024 milestones with patient-friendly, differentiated protocols - TradingView
DNTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Tuesday - Defense World
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A 37% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next - TechStock²
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference - Bitget
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.1%Time to Buy? - MarketBeat
Patient Square Capital LP Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (DNTH): Analyst Consensus Points to a Promising 46.82% Upside Potential - DirectorsTalk Interviews
Ideas Watch: Whats the RSI of Dianthus Therapeutics Inc stockOil Prices & High Return Trade Guides - baoquankhu1.vn
RA Capital discloses 6.0% Dianthus Therapeutics (DNTH) ownership stake - Stock Titan
Point72 boosts Dianthus Therapeutics (DNTH) stake to 6.9% passive ownership - Stock Titan
Transcript : Dianthus Therapeutics, Inc. Presents at Guggenheim Securities Emerging Outlook - marketscreener.com
Assessing Dianthus Therapeutics (DNTH) Valuation After A Strong Year And Recent Share Price Pullback - Sahm
Will Dianthus Therapeutics Inc. (87E) stock beat international competitionPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans - MarketBeat
Will Dianthus Therapeutics Inc. stock go up in YEARPortfolio Value Summary & Verified Short-Term Plans - mfd.ru
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success - TradingView
DNTH: Pivotal trial readouts and strong financials position the pipeline for major commercial impact - TradingView
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics - Benzinga
Can Dianthus Therapeutics Inc. deliver alpha2025 Winners & Losers & Verified Momentum Stock Alerts - mfd.ru
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00 - MarketBeat
Is Dianthus Therapeutics Inc. a turnaround storyBear Alert & Verified Momentum Stock Alerts - mfd.ru
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration - simplywall.st
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing - Sahm
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - 富途牛牛
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99 - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group - MarketBeat
Will Dianthus Therapeutics Inc. stock keep outperforming rivalsJuly 2025 EndofMonth & Weekly Top Stock Performers List - mfd.ru
Biotech Stocks To Follow Today – January 30th - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com - Investing.com India
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 21.98% Upside Potential - DirectorsTalk Interviews
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD - Investing.com
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating - marketscreener.com
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):